Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) Shares Outstanding (Weighted Average) (2019 - 2024)

Historic Shares Outstanding (Weighted Average) for Bioadaptives (BDPT) over the last 6 years, with Q4 2024 value amounting to $8.2 million.

  • Bioadaptives' Shares Outstanding (Weighted Average) rose 3757.2% to $8.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.2 million, marking a year-over-year increase of 3757.2%. This contributed to the annual value of $8.2 million for FY2024, which is 3757.2% up from last year.
  • According to the latest figures from Q4 2024, Bioadaptives' Shares Outstanding (Weighted Average) is $8.2 million, which was up 3757.2% from $1.1 billion recorded in Q3 2024.
  • Bioadaptives' Shares Outstanding (Weighted Average)'s 5-year high stood at $1.1 billion during Q3 2024, with a 5-year trough of $6.0 million in Q4 2023.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $43.8 million (2021), whereas its average is $260.6 million.
  • Data for Bioadaptives' Shares Outstanding (Weighted Average) shows a peak YoY increase of 71716.54% (in 2023) and a maximum YoY decrease of 9436.69% (in 2023) over the last 5 years.
  • Quarter analysis of 5 years shows Bioadaptives' Shares Outstanding (Weighted Average) stood at $20.4 million in 2020, then skyrocketed by 65.51% to $33.7 million in 2021, then skyrocketed by 214.17% to $106.0 million in 2022, then tumbled by 94.37% to $6.0 million in 2023, then surged by 37.57% to $8.2 million in 2024.
  • Its Shares Outstanding (Weighted Average) was $8.2 million in Q4 2024, compared to $1.1 billion in Q3 2024 and $1.1 billion in Q2 2024.